Generation Bio Co.
| NASDAQ: GBIO |
| Healthcare / Biotechnology / USA |
| 26.60 | +0.7600 | +2.94% | Vol 218.94K | 1Y Perf -9.97% |
| Sep 15th, 2021 16:00 DELAYED |
| BID | 26.57 | ASK | 26.62 | ||
| Open | 25.94 | Previous Close | 25.84 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 39.80 | Analyst Rating | — — 0.00 | |
| Potential % | 49.62 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 20.35 | Earnings Rating | — | |
| Market Cap | 1.51B | Earnings Date | 9th Nov 2021 | |
| Alpha | -0.10 | Standard Deviation | 0.35 | |
| Beta | 5.56 |
Today's Price Range 25.4327.52 | 52W Range 19.1655.72 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 4.19% | ||
| 1 Month | 17.39% | ||
| 3 Months | -0.34% | ||
| 6 Months | -21.86% | ||
| 1 Year | -9.97% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -27.50 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -24.68 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -24.35 | |||
Return on invested Capital Q | -6.24 | |||
Return on invested Capital Y | -95.06 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -15.40 | ||||
| 3.51 | ||||
| - | ||||
| - | ||||
| -16.70 | ||||
| -1.68 | ||||
| 3.51 | ||||
| 7.63 | ||||
| 1.14B | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 30.50 | ||||
| 31.10 | ||||
| 0.09 | ||||
| 0.11 | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2021 | -0.47 | -0.55 | -17.02 |
| Q01 2021 | -0.46 | -0.46 | 0.00 |
| Q04 2020 | -0.52 | -0.53 | -1.92 |
| Q03 2020 | -0.45 | -0.46 | -2.22 |
| Q02 2020 | -0.60 | -1.50 | -150.00 |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 9th Nov 2021 |
| Estimated EPS Next Report | -0.55 |
| Estimates Count | 5 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 218.94K |
| Shares Outstanding | 56.78M |
| Shares Float | 30.08M |
| Trades Count | 3.76K |
| Dollar Volume | 18.59M |
| Avg. Volume | 471.61K |
| Avg. Weekly Volume | 300.02K |
| Avg. Monthly Volume | 287.97K |
| Avg. Quarterly Volume | 300.91K |
Generation Bio Co. (NASDAQ: GBIO) stock closed at 26.6 per share at the end of the most recent trading day (a 2.94% change compared to the prior day closing price) with a volume of 222.28K shares and market capitalization of 1.51B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 85 people. Generation Bio Co. CEO is Geoffrey McDonough.
The one-year performance of Generation Bio Co. stock is -9.97%, while year-to-date (YTD) performance is -6.17%. GBIO stock has a five-year performance of %. Its 52-week range is between 19.16 and 55.72, which gives GBIO stock a 52-week price range ratio of 20.35%
Generation Bio Co. currently has a PE ratio of -15.40, a price-to-book (PB) ratio of 3.51, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -24.68%, a ROC of -24.35% and a ROE of -27.50%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Generation Bio Co., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.55 for the next earnings report. Generation Bio Co.’s next earnings report date is 09th Nov 2021.
The consensus rating of Wall Street analysts for Generation Bio Co. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Generation Bio Co. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Generation Bio Co. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Generation Bio Co. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.18, ATR14 : 1.88, CCI20 : 99.40, Chaikin Money Flow : -0.04, MACD : 0.80, Money Flow Index : 68.35, ROC : 3.91, RSI : 57.65, STOCH (14,3) : 60.42, STOCH RSI : 0.44, UO : 45.69, Williams %R : -39.58), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Generation Bio Co. in the last 12-months were:
Generation Bio Co.
Generation Bio Co is a genetics medicine company which is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina related diseases.
CEO: Geoffrey McDonough
Telephone: +1 617 655-7500
Address: 301 Binney Street, Cambridge 02142, MA, US
Number of employees: 85
